sanofi-aventis

A Busy Month in the Business of microRNA

by Chris on June 30, 2010

BUSINESSWIRE -

June 29th – Alnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR)

June 29th – Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer

June 28th – Reimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel Through World’s Second Largest HMO

June 28th – Alnylam Scientists and Collaborators Publish Research in Nature Chemical Biology on a Novel Mechanism for Regulation of Gene Expression with Anti-Gene RNAs (agRNAs)

June 23rd – Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-Targeted Medicines for the Treatment of Cardiovascular Disease

June 23rd – Alnylam Biotherapeutics Presents New Data on RNAi Applications in Biotherapeutics Manufacturing

June 22nd – Isis and Alnylam Provide Update on Regulus’ Strategic Alliance with Sanofi-Aventis

June 22nd – Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

June 21st – Mirna Therapeutics Recommended for $10 Million Commercialization Award from the Cancer Prevention and Research Institute of Texas

June 17th – Alnylam Secures Intellectual Property and Technology for RNAi Applications in Vaccine Research and Development

June 17th – Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics that Target Mutated Genes

June 7th – Data Presented at ASCO 2010 by M. D. Anderson Researchers Demonstrate the ability of miRview™ mets to Identify the Most Likely Origin of Metastases in Cancer of Unknown Primary

June 3rd – Rosetta Genomics Establishes “Rosetta Green” as Majority-owned Subsidiary


Incoming search terms for this article:

{ 1 comment }

Largest microRNA Therapeutics Alliance To Date

by Chris on June 22, 2010

Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

Carlsbad, CA., June 22, 2010 – Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics.  The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.  The alliance will initially focus on the therapeutic area of fibrosis.  Regulus and sanofi-aventis will collaborate on up to four microRNA targets, including Regulus’ lead fibrosis program targeting microRNA-21.  sanofi-aventis also receives an option for a broader technology alliance that provides Regulus certain rights to participate in development and commercialization of resulting products.  If exercised, this three-year option is worth an additional $50 million to Regulus. (read more… )

Incoming search terms for this article:

{ 0 comments }